09:01 AM EDT, 06/18/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday that results of a phase 3 trial support the use of Hyqvia as maintenance treatment for chronic inflammatory demyelinating polyneuropathy or CIDP, an acquired, immune-mediated condition that affects the peripheral nervous system.

Data showed Hyqvia's favorable long-term safety, tolerability and low relapse rate, the company said.

Earlier this year, Hyqvia was approved by the US Food and Drug Administration as maintenance therapy in adults with CIDP and by the European Commission for patients with CIDP post-stabilization with intravenous immunoglobulin, according to the company.

Price: 12.84, Change: -0.33, Percent Change: -2.51